可靠股份管理层矛盾激化独董遭罢免 董事鲍佳243万高薪事件成争论焦点

Core Viewpoint - The conflict between the chairman of Kexin Co., Ltd. Jin Liwei and director Bao Jia has intensified, leading to the dismissal of independent director Jing Naiquan, who has been accused of losing independence [1][5][7]. Group 1: Company Governance Issues - Kexin Co., Ltd. announced the dismissal of independent director Jing Naiquan, with 5 out of 7 board members voting in favor, while Bao Jia and Jing Naiquan opposed the motion [4][5]. - The company claims that Jing Naiquan failed to fulfill his duties and lacked the professional ethics expected of an independent director, leading to the decision to terminate his position [5][7]. - Bao Jia argues that the dismissal is a retaliatory action by Jin Liwei against Jing Naiquan for maintaining independent judgment and opposing Bao Jia's interests [6][11]. Group 2: Compensation Controversy - The central issue of the dispute revolves around Bao Jia's high salary of 2.43 million yuan, which he claims is justified, while the company argues it is inappropriate given his lack of service in 2025 [3][10][11]. - Kexin Co., Ltd. has raised concerns about Jing Naiquan's actions during discussions about Bao Jia's compensation, suggesting that he exhibited a bias that undermined his independence [8][9]. - Bao Jia asserts that Jin Liwei's actions regarding his salary and role in the company demonstrate a breach of trust and integrity [10][11].

Coco Healthcare-可靠股份管理层矛盾激化独董遭罢免 董事鲍佳243万高薪事件成争论焦点 - Reportify